FAIR VALUE DISCLOSURES (Details Textual) - USD ($) $ in Thousands		1 Months Ended			6 Months Ended
		Feb. 28, 2017	Apr. 30, 2016	Jan. 31, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate					15.00%
Payments to Acquire Intangible Assets					$ 50,956	$ 144,494
Long-term Debt, Total					124,381		$ 120,643
Finite-Lived Intangible Assets, Gross					238,048		203,992
Inventory, Finished Goods, Gross	[1]				23,279		$ 10,812
Accrued Royalties Related To Asset Purchase					0	$ 3,882
Cranford Pharmaceuticals [Member] | Non Compete Agreement [Member]
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate			10.00%
Finite-Lived Intangible Assets, Gross			$ 600
Finite-Lived Intangible Asset, Useful Life			7 years
Inderal XL [Member]
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate		10.00%
Finite-Lived Intangible Assets, Gross		$ 15,100
Finite-Lived Intangible Asset, Useful Life		10 years
Acquisition Costs Capitalized		$ 40
Inventory, Finished Goods, Gross		5,000
Asset Acquisition Purchase Price		$ 20,200
InnoPran XL [Member]
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate		10.00%
Finite-Lived Intangible Assets, Gross		$ 19,000
Finite-Lived Intangible Asset, Useful Life		10 years
Acquisition Costs Capitalized		$ 100
Inventory, Finished Goods, Gross		11,600
Asset Acquisition Purchase Price		30,600
InnoPran XL [Member] | Cash [Member]
Fair Value Inputs, Assets, Quantitative Information
Payments to Acquire Intangible Assets		600
InnoPran XL [Member] | Line of Credit [Member]
Fair Value Inputs, Assets, Quantitative Information
Payments to Acquire Intangible Assets		$ 30,000
Merck Sharp Dohme B.V. [Member]
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate				10.00%
Finite-Lived Intangible Assets, Gross				$ 75,000
Finite-Lived Intangible Asset, Useful Life				10 years
Acquisition Costs Capitalized				$ 300
Fair Value, Inputs, Level 1 [Member]
Fair Value Inputs, Assets, Quantitative Information
Notes Payable, Fair Value Disclosure					$ 151,000
New Drug Applications [Member] | Cranford Pharmaceuticals [Member]
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate			12.00%
Payments to Acquire Intangible Assets			$ 60,000
Finite-Lived Intangible Assets, Gross			$ 52,400
Finite-Lived Intangible Asset, Useful Life			10 years
Acquisition Costs Capitalized			$ 300
Inventory, Finished Goods, Gross			10,900
Funds Held In Escrow In Relation To Asset Purchase			5,000
Accrued Royalties Related To Asset Purchase			3,900
Asset Acquisition Purchase Price			$ 64,200

[1] Includes finished goods acquired in asset purchases (Note 12).